title: Nevirapine use in HIV-1-infected children.
abstract: OBJECTIVE
  To evaluate the safety, efficacy, and clinical, virological, and immunological responses in HIV-1-infected children receiving nevirapine as part of combination antiretroviral therapy (ART).
  
  
  METHODS
  A review of case notes of all HIV-1-infected children 96 weeks after starting nevirapine, under a national compassionate access scheme between August 1997 and March 1999 in the UK. Nevirapine was dosed according to the manufacturer's guidelines.
  
  
  RESULTS
  Seventy-four children (36 boys, 28 naive to ART) were enrolled, with a median age of 5.2 years, viral load of 5.1 log copies/ml and CD4 lymphocyte count of 13.5%. The liquid formulation and tablets of nevirapine were well tolerated. The proportions of patients achieving undetectable viral load levels at weeks 12, 24, 48 and 96 were 30, 40, 36 and 33%, respectively (intention-to-treat analysis). Of children not on a protease inhibitor who received more than 300 mg/m2/day of nevirapine, 60% had undetectable viral loads at week 96, compared with 17% on recommended doses. Outcomes were similar for patients receiving nevirapine once or twice daily. CD4 cell count percentages increased significantly, with median values sustained above 25% by week 48 onwards. Z-scores for weight and height increased significantly during 96 weeks of treatment. Rash occurred in 20%, of which four (5%) were severe. There were no cases of Stevens-Johnson syndrome.
  
  
  CONCLUSIONS
  Nevirapine was mostly well tolerated, and was associated with encouraging clinical and immunological responses. Virological responses in this cohort support the use of nevirapine doses greater than 300 mg/m2/day, which is higher than currently recommended by the manufacturers.
authors.affiliation: Imperial College, London, UK.
authors.forename: Gwenda
authors.initials: G
authors.lastname: Verweel
authors.forename: Mike
authors.initials: M
authors.lastname: Sharland
authors.forename: Hermione
authors.initials: H
authors.lastname: Lyall
authors.forename: Vas
authors.initials: V
authors.lastname: Novelli
authors.forename: Diane M
authors.initials: DM
authors.lastname: Gibb
authors.forename: Gillian
authors.initials: G
authors.lastname: Dumont
authors.forename: Colin
authors.initials: C
authors.lastname: Ball
authors.forename: Ed
authors.initials: E
authors.lastname: Wilkins
authors.forename: Sam
authors.initials: S
authors.lastname: Walters
authors.forename: Gareth
authors.initials: G
authors.lastname: Tudor-Williams
mesh_terms: D000293:Adolescent; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D001827:Body Height; D018791:CD4 Lymphocyte Count; D002648:Child; D002675:Child, Preschool; D003430:Cross-Sectional Studies; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D004890:Erythema / Q000139:chemically induced; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D006801:Humans; D007223:Infant; D008297:Male; D019829:Nevirapine / Q000009:adverse effects / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D018709:Statistics, Nonparametric; D019562:Viral Load
chemical_list: D019380:Anti-HIV Agents; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine